Скачать или смотреть RGNX Stock Still Has Over 300% Upside Despite FDA Pushback - How Reliable?

Clear Street kept a 'Buy' rating, cut its price target to $45 from $50, and said its core thesis remains intact.
The FDA said more evidence is needed to support approval of RGX-121 for Hunter syndrome.
Regenxbio plans a Type A meeting with the FDA and aims to resubmit the BLA with additional expert input and longer-term data.

Shares of Regenxbio, Inc. plunged about 19% after hours on Monday after the FDA issued a Complete Response Letter (CRL) for its Hunter syndrome gene therapy. Still, Clear Street kept a 'Buy' rating and said its core thesis on RGNX remains intact. - https://www.tradingview.com/news/stoc...
Join this channel to get access to perks:
   / @equity4keeps  

Consider Supporting this Channel via PayPal: https://www.paypal.com/donate/?hosted...